Evaluation of CA125 and NT-proBNP values in patients undergoing transcatheter aortic valve implantation

BackgroundTranscatheter 大动脉的阀门培植(TAVI ) 是在通过手术高的风险，或不能实行的病人的最低限度地侵略的、新兴的治疗。为风险分类使用的参数在病人的选择有一些缺乏。学习是在糖类抗原 125 上评估 TAVI 的影响的这的目的(CA125 ) 和 N 终端职业人员大脑类型 Natriuretic 肽(NT-proBNP ) 作为在最近的年里经常被使用了的 biomarkers，并且也到 prognosis.Methods &#x00026 的这些 biomarkers 的关系；ResultsTranscatheter 大动脉的阀门培植在这研究在 31 个病人上被练习。然后，在病人学习在以前并且在 TAVI 以后的 CA125 和 NT-proBNP 层次被评估。病人也根据他们的左室的喷射部分(LVEF ) 被组织， CA125 铺平(LVEF &#x02265；40% 并且 &#x0003c；40% ；CA125 &#x02264；35 U/L 和 &#x0003e；35 U/L ) 。TAVI 手术成功地在所有病人被动。没有在里面医院死亡，在功能的能力的实质的改进在跟帖被检测。另外，统计上重要的减少在所有病人的 post-TAVI CA125 和 NT-proBNP 层次被检测(CA125 83.8 &#x000b1；18.1 U/L 对 64.3 &#x000b1；14.2 U/L， P = 0.008；NT-proBNP：4633.6 &#x000b1；627.6 pg/mL 对 2866.3 &#x000b1；536.8 pg/mL， P &#x0003c；0.001 ) 。在根据 CA125 层次划分的组，也在 CA125 层次有统计上重要的 post-TAVI 衰落。在 CA125 &#x0003e 以内；35 U/L 和 LVEF &#x0003c；40% 组，对一个心律调整器的永久需要在(3.2%) 被要求病人和死亡在二被观察(6.4%) 在 TAVI 在以后的病人跟随 TAVI 能与 CA125 和 NT-proBNP 的高基线层次在病人有效地并且可靠地被执行的 up.ConclusionsThe 结果表演。当高 biomarker 层次与不希望得到的事件被联系时，这些 biomarkers 与 TAVI 实质地被减少，并且当然，这些 biomarkers 能为 TAVI 在耐心的选择被用于风险分类。

Background Transcatheter aortic valve implantation （TAVI） is a minimally invasive, emerging therapy in surgically high risk, or in- operable patients. Parameters used for risk classification have some deficiencies in the selection of patients. The objective of this study is to evaluate the impact of TAVI on carbohydrate antigen 125 （CA125） and N-terminal pro brain-type natriuretic peptide （NT-proBNP） as biomarkers that have been used frequently in recent years, and also the relationship of these biomarkers to prognosis. Methods ＆ Results Transcatheter aortic valve implantation was practiced on 31 patients in this study. Then, CA125 and NT-proBNP levels studied in patients prior to and after the TAVI were evaluated. The patients were also grouped in accordance with their left ventrieular ejection fraction （LVEF） and CA125 levels （LVEF 〉 40% and 〈 40%; CA125 ≤ 35 U/L and 〉 35 U/L）. The TAVI operation was successfully performed in all patients. There was no in-hospital mortality and substantial improvement in functional capacity was detected at follow ups. In addition, a statistically significant decrease was detected in post-TAVI CA 125 and NT-proBNP levels of all patients （CA 125 83.8 ± 18.1 U/L vs. 64.3 ±14.2 U/L, P = 0.008; NT-proBNP： 4633.6± 627.6 pg/mL vs. 2866.3±536.8 pg/mL, P 〈 0.001）. In groups divided according to the CA125 levels, there was also statistically significant post-TAVI decline in CA125 levels. Within CA125 〉 35 U/L and LVEF 〈 40% groups, the permanent need for a pacemaker was required in one （3.2%） patient and mortality was observed in two （6.4%） patients after TAVI at follow up. Conclusions The results show that TAVI can be performed effectively and reliably in patients with high baseline levels of CA125 and NT-proBNP. These biomarkers are reduced substantially with TAVI, while high biomarker levels are associated with undesired events, and certainly, these biomarkers can be used for risk classifications in patient selection for TAVI.